Conference Reports for NATAP

Back

APASL 25th Conference of the Asian Pacific Association for the Study of the Liver Feb 20-24 2016, Tokyo, Japan     SOF/Velpatasvir, +GS-9857 - Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study - (04/12/16)   Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies - (04/01/16)   Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study - (04/01/16)   Flares in patients treated with Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) - (02/26/16)   Comparison of Asians vs. Non-Asians treated with TDF Plus Peginterferon (PEG) - (02/26/16)   Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients - (02/23/16)   SAFETY AND EFFICACY OF ORAL REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1b INFECTION: HCV---TARGET INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY HCV-TARGET Study Group - (02/23/16)   Integrated Safety and Tolerability of DCV + ASV in Patients with Chronic HCV Genotype 1b Infection - (02/23/16)   All-Oral Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination Therapy for HCV Genotype 1..... Enrolled in South Korea, Taiwan, and Russia.....mostly HCV GT 1b infection, up to 20% with compensated cirrhosis - (02/23/16)   Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination in Treatment-Naive and Interferon-Experienced Japanese Patients With HCV Genotype 1 Infection: UNITY-3 Study - (02/23/16)   DCV + ASV in IFN (± RBV) Ineligible/Intolerant Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection - (02/23/16)   Safety and Tolerability of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (02/23/16)   Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials - (02/23/16)   GIFT-I: DURABILITY OF RESPONSE OF OMBITASVIR/PARITAPREVIR/RITONAVIR IN HCV GT1B JAPANESE PATIENTS - (02/23/16)   GIFT-I: ALT CHANGES WITH OMBITASVIR/PARITAPREVIR/RITONAVIR AND CONCOMITANT USE OF HEPATOPROTECTIVES - (02/22/16)   High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 weeks with or without Ribavirin in Treatment-NaÏve, Non-Cirrhotic HCV GT1b Infected Patients: an Integrated Analysis - (02/22/16)   Elbasvir/Grazoprevir in Cirrhotic Patients With HCV Infection - (02/22/16)   Sofosbuvir, Ledipasvir in IBD treated patients with advanced biologics including Ribavirineradicating Chronic Hepatitis C: SOLATAIRE CTrial. A multi-center clinical prospectivepilot study - (02/22/16)   GIFT-I: OMBITASVIR/PARITAPREVIR/RITONAVIR SAFETY AND EFFICACY IN RENALLY-IMPAIRED JAPANESE PATIENTS - (02/22/16)   GIFT-I: SAFETY AND EFFICACY OF OMBITASVIR/PARITAPREVIR/RITONAVIR IN ELDERLY JAPANESE PATIENTS - (02/22/16)   Evaluation of Daclatasvir and Asunaprevir Exposures in Japanese, Non Japanese Asians, and Non-Asians - (02/22/16)   EQ-5D Results in Asian Patients with HCV Genotype 1b Receiving Daclatasvir plus Asunaprevir who are Interferon Intolerant/Ineligible - (02/22/16)   FSS and SF-36 in Asian Patients with HCV Genotype 1b Receiving Daclatasvir and Asunaprevir and who are Interferon plus Ribavarin Intolerant or Ineligible - (02/22/16)   Daclatasvir+Asunaprevir versus Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Genotype 1 in Japanese Patients: A Matching-Adjusted Indirect Comparison - (02/22/16)   High SVR Rates With ABT-493 + ABT-530 in Non-Cirrhotic Patients With HCV Genotypes 1, 2, 3 Infection - (02/22/16)   SLAM C study Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. (drug rehabs in NYC] - (02/22/16)